Analysts have been eager to weigh in on the Healthcare sector with new ratings on Acceleron Pharma (XLRN), Savara (SVRA) and Nabriva (NBRV).
Acceleron Pharma (XLRN)
In a report released today, Leland Gershell from Oppenheimer assigned a Buy rating to Acceleron Pharma, with a price target of $120.00. The company’s shares closed last Thursday at $109.49.
According to TipRanks.com, Gershell is a 2-star analyst with an average return of 0.4% and a 37.9% success rate. Gershell covers the Healthcare sector, focusing on stocks such as Milestone Pharmaceuticals, BioMarin Pharmaceutical, and Corbus Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Acceleron Pharma with a $127.17 average price target, representing a 12.7% upside. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $148.00 price target.
See today’s analyst top recommended stocks >>
Savara (SVRA)
Ladenburg Thalmann & Co. analyst Michael Higgins maintained a Hold rating on Savara today and set a price target of $1.30. The company’s shares closed last Thursday at $1.12, close to its 52-week low of $0.69.
According to TipRanks.com, Higgins is a 4-star analyst with an average return of 12.8% and a 33.3% success rate. Higgins covers the Healthcare sector, focusing on stocks such as Eiger Biopharmaceuticals, Zynerba Pharmaceuticals, and Armata Pharmaceuticals.
Currently, the analyst consensus on Savara is a Hold with an average price target of $1.30.
Nabriva (NBRV)
Needham analyst Alan Carr maintained a Hold rating on Nabriva today. The company’s shares closed last Thursday at $0.49, close to its 52-week low of $0.47.
According to TipRanks.com, Carr is a 3-star analyst with an average return of 1.5% and a 43.0% success rate. Carr covers the Healthcare sector, focusing on stocks such as Phathom Pharmaceuticals, Lexicon Pharmaceuticals, and Crispr Therapeutics AG.
Nabriva has an analyst consensus of Moderate Buy, with a price target consensus of $1.50.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
